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Abstract: Poststroke depression (PSD) in elderly patients has been considered the most common 
neuropsychiatric consequence of stroke up to 6–24 months after stroke onset. When depression 
appears within days after stroke onset, it is likely to remit, whereas depression at 3 months is likely 
to be sustained for 1 year. One of the major problems posed by elderly stroke patients is how to 
identify and optimally manage PSD. This review provides insight to identification and manage-
ment of depression in elderly stroke patients. Depression following stroke is less likely to include 
dysphoria and more likely characterized by vegetative signs and symptoms compared with other 
forms of late-life depression, and clinicians should rely more on nonsomatic symptoms rather 
than somatic symptoms. Evaluation and diagnosis of depression among elderly stroke patients 
are more complex due to vague symptoms of depression, overlapping signs and symptoms of 
stroke and depression, lack of properly trained health care personnel, and insufficient assessment 
tools for proper diagnosis. Major goals of treatment are to reduce depressive symptoms, improve 
mood and quality of life, and reduce the risk of medical complications including relapse. Anti-
depressants (ADs) are generally not indicated in mild forms because the balance of benefit and 
risk is not satisfactory in elderly stroke patients. Selective serotonin reuptake inhibitors are the 
first choice of PSD treatment in elderly patients due to their lower potential for drug interaction 
and side effects, which are more common with tricyclic ADs. Recently, stimulant medications 
have emerged as promising new therapeutic interventions for PSD and are now the subject of 
rigorous clinical trials. Cognitive behavioral therapy can also be useful, and electroconvulsive 
therapy is available for patients with severe refractory PSD.
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Scope of the problem: aging, stroke,  
and poststroke depression
Incidence of stroke increases sharply with age,1 a fact that each successive decade above 
55 years leads to a doubling of stroke incidence.2 According to a recent population-
based stroke study in Europe, 70.2% of stroke patients were older than 65 years, and 
the median age was 73 years (interquartile range, 62–81).3 The combined impact of 
increased life expectancy and medical management advancements has resulted in a 
larger number of elderly persons surviving stroke.4
The physical and psychological sequelae caused by stroke can be devastating.5 
Poststroke depression (PSD) is one of the unresolved issues in recovery and rehabilita-
tion of the stroke patients. It has been considered the most common neuropsychiatric 
consequence of stroke.6 Depression may either directly or indirectly lead to more 
significant impairments in daily activities, which require more careful services and Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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  institutionalization of stroke patients.7–9 The risk of fatality 
is higher in stroke patients with depression compared with 
nondepressed stroke patients.10 Deteriorated cognitive func-
tion and increased medical complication rates among patients 
with PSD adversely influence the speed of recovery and the 
level of residual function following rehabilitation.11–12 Other 
consequences of PSD include higher health care costs, dimin-
ished social abilities, and an increased risk of vascular-related 
events and death.13,14
One of the major problems posed by elderly stroke 
patients is how to identify and optimally manage PSD, which 
is more common in elderly stroke patients than younger 
stroke patients. The aim of this review is to provide insight 
to symptoms, identification, diagnosis, and management of 
depression in elderly stroke patients.
Search strategy and selection 
criteria
References for this review were recognized through search 
in PubMed for potentially relevant articles with the search 
terms of “depression” and “depressive disorder” in combi-
nation with “elderly,” “older,” “stroke,” “cerebrovascular,” 
and “ischemia.” Preference was given to articles published 
between January 1981 and January 2010. Only articles pub-
lished in English were reviewed. The final citation list was 
selected based on relevance to PSD in elderly patients. Our 
search strategy identified 2,547 nonduplicated references of 
which 274 articles were considered relevant. After   reviewing 
abstracts, 150 articles were examined in detail, yielding 
67 articles to match the eligibility criteria.
Epidemiology of PSD
Depression is a common consequence of stroke up to 2–3 
years after stroke onset.15 Prevalence rates of PSD vary from 
6% to 79%.16,17 These rates show considerable variation 
between studies and amongst different populations. PSD 
rates depend on the setting in which patients are examined, 
demonstrating greater rates among hospital inpatient-based 
locations (acute stroke units, general hospital wards, or 
rehabilitation centers) than community-based settings.5,18 
Differences in definitions of PSD and patient selection 
criteria (including prior patient history of depression) com-
bined with disparity among evaluation instruments resulted 
in large variability between studies, making results difficult 
to interpret.17,19 In the acute period (,1 month after stroke), 
the frequency of depressive disorders was found to be 30%, 
33%, and 36% in rehabilitation, community, and hospital-
based settings, respectively.20 Approximately 1–6 months 
after stroke, the frequency of depressive disorders was 
somewhat higher in rehabilitation settings (36%)   compared 
with community- and hospital-based settings.20 Most studies 
examined the risk of depression in younger patient popula-
tions, whereas only few studies investigated that in elderly 
stroke patients. Few studies relate the frequency of PSD 
adjusted for age or sex.21,22 The prevalence of depressive 
disorders in those older than 55 years (when stroke commonly 
occurs) has been estimated to be 18% in women and 11% 
in men.23 Even this figure may be an underestimation due to 
exclusion of patients with impaired communication, such as 
patients with aphasia (including 25% of the stroke patients) 
or patients with dementia.24 Among a population of elderly 
residents in the United States, a community survey on the 
prevalence of depression showed 42.9% for men and 64.1% 
for women, generally a high rate of stroke survivors.25 Linden 
et al26 showed that the frequency of depressive disorders in 
a consecutive series of hospitalized elderly stroke patients 
20 months after stroke onset was 34% in the stroke patients 
and 13% in controls. Patients recruited for this study were 
selected from hospitalized stroke patients, who were more 
severely affected in general. Because most stroke patients in 
Sweden are treated in hospitals (even those with mild symp-
toms), the authors considered that their sample reasonably 
reflects the total elderly stroke population.26
Pathophysiology of PSD
The primary biological mechanism is proposed to be the 
cause of PSD, whereby ischemic insults directly affect neural 
circuits involved in mood regulation.27,28 An injury to the 
brain’s catecholamine pathway reduces the release of neu-
rotransmitters with a likely depression as a result. A   depletion 
in cortical biogenic amines is found after a disruption of 
frontal-subcortical circuits after stroke.29   However, there are 
also arguments for a psychological basis of PSD put forth 
by researchers. This relates to the similarity of symptoms 
and treatment response profiles between PSD and functional 
depression. Carson et al30 performed a meta-analysis in 
which they noted that the risk of depression did not relate 
to the location of the cerebral lesion. However, most PSD 
appears to be multifactorial in origin. However, some stroke 
survivors may have a PSD purely biological in origin, and 
some purely psychological.
Clinical manifestations of PSD
PSD occurring within the first 3 months of stroke is classified 
as “early” and is defined as “late” when the symptoms appear 
later.31 Early PSD patients have more depressive somatic Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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signs compared with psychological symptoms32 and more 
frequently show early symptoms of melancholy, vegetative 
signs, and psychological disturbances.33 PSD may appear 
shortly after stroke but usually develops several months after 
a cerebrovascular event.18 Peak incidence and greatest sever-
ity of depression commonly occur between 6 months and 
2 years after stroke.34 Robinson et al34 found major depression 
in assessments immediately after a stroke in almost one-third 
of patients and noted that 60% of those patients still were 
depressed 1 year later. Depressive symptoms at any level of 
severity can be recognized in 18%–30% of patients during 
3–5 years after stroke.35–37
Depression presents differently among patients with 
neurological syndromes.24 Depression following stroke, 
especially stroke with right hemisphere damage, is less 
likely to include dysphoria and more likely characterized by 
vegetative signs and symptoms compared with other forms 
of late-life depression.38 In 2004, Mast39 showed that stroke 
patients were more likely to exhibit social withdrawal and 
were less likely to exhibit agitation compared with geriatric 
depression accompanying other medical illnesses, although 
there were no differences in depressed mood or energy 
between them. Robinson and his coworkers40,41 suggested that 
somatic symptoms are more common among stroke patients 
when depressed mood is present. In this case, clinicians are 
more sensitive to similarities between somatic features, com-
monly seen in older medical patients, and clinical features 
typical of depression.42 For the most accurate diagnoses, 
clinicians should rely more on nonsomatic symptoms rather 
than somatic symptoms.43 Some symptoms are common 
to both stroke and depression, such as sleep disturbances, 
concentration difficulties, and reduced appetite, which might 
cause an overestimation of depression in stroke patients.44 In 
older people with cognitive impairments due to aging and 
degenerative disorders, additional cognitive impairments 
caused by depression can be more troublesome.45 About 
2%–3% of patients without stroke show “masked” depres-
sion (depressive symptoms without an associated depressed 
mood) with manifestations of biological rhythm impairment 
(like sleeplessness or hypersomnia) and somatization, par-
ticularly autonomic vascular dystonia, vertigo, or various 
dysalgic phenomena.46
Depressive disorders in older  
vs younger adults
Clinically, there are differences between depressed younger 
and older people. When comparing elderly adult depression 
vs young adult depression, there is a dynamic increase in the 
level of somatic symptoms, including loss or lack of interests 
and other affective symptoms, such as dysphoria, worthless-
ness, or guilt.24 Somatic symptoms often obscure depression 
in older people either because of the somatic nature of the 
disorder or because of the escalation of symptoms of an 
existing physical illness47 (Table 1). Older patients seldom 
have evident signs of low mood, so they do not meet the 
Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, (DSM-IV) criteria for major depression.47 
It has been shown that older adults focus more on positive 
and emotionally meaningful experiences, which provides 
better emotion regulation with advancing age.48 In contrast 
to younger depressed patients, elderly patients often hide 
their mood with the mentality that decreased life fulfillment 
is a normal consequence of aging and disease (stroke).49 
Among depressed older adults, subjective complaints of poor 
memory and lack of concentration are common, whereas 
symptoms of fatigue, sleep disturbance, psychomotor retar-
dation, and hopelessness about the future are more common 
among depressed younger adults.50
Factors contributing to the risk 
of PSD
Several factors that impact the risk of PSD development 
have been identified. Social isolation, living alone, physical 
functional impairments, or a history of depression (or other 
psychiatric disorder) are identified as predictive risk factors 
for PSD.51–53 However, not all studies confirm the association 
between PSD and social factors, such as poststroke social 
isolation and living alone.53 Some symptoms associated with 
PSD are the same as the risk factors, such as reduced social 
activity, failure to return to work, and poor participation in 
processes of rehabilitation.54
Gender has been found to be mildly associated with PSD. 
Some authors have reported that PSD is twice as common 
in women as in men,55 whereas others found that older, 
physically disabled men with inadequate social support 
Table 1   Differences  in  clinical  picture  between  younger  and 
elderly patients with depressive disorders47
Younger patients Elderly patients
Depressed mood +++ +(+)
Cognitive impairment + +++
Retardation ++ ++
Somatic symptoms + +++
Anxiety +(+) +++
Psychotic symptoms (+) ++
Hypochondria + ++
Note: +, higher scores of symbols indicate more symptoms.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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were more likely to experience PSD.56 Major depression in 
women has been associated with higher education level, prior 
psychiatric diagnoses, and cognitive impairments.56 Women 
mostly have early PSD, whereas men were more likely to 
have late PSD.15
There is no clear relationship between the severity of 
stroke and the occurrence of PSD.57 Research has shown 
that 50% of those who have experienced a stroke 3 months 
ago are more plausible to be depressed yet another year. 
Another difference between those patients who are shown 
to be depressed within days after stroke is the likelihood to 
show remission.58 Some investigators found depression to be 
more likely among persons with large lesions59 and severe 
stroke injury scores,60 but other studies have not confirmed 
this.61 Questions have arisen whether the site of infarct can 
influence the PSD development.62 In a meta-analysis of 
35 studies conducted by Carson et al30 no data conclusively 
supported an association between intrahemispheric location 
and the risk of depression. Desmond et al42 did not recognize 
an association between lesion location and depression in older 
stoke patients. However, other studies found an increased 
risk of PSD with left-brain lesions.63 Linden et al26 found no 
association between the predominant side of symptoms at the 
time of the stroke onset and depressive syndromes. Likewise, 
there is a chance that lesion location is related to depression 
in the acute phase of stroke.26 This inconsistency of results 
might be related to study design, assessors, and assessment 
tools for diagnosing PSD. In most studies that showed a 
relationship between PSD and right-hemisphere lesions, 
patients with left-hemisphere damage were excluded due to 
the language problem caused by stroke. In contrast, in studies 
showing a moderate relationship between left-hemisphere 
lesion and PSD, stroke patients with language dysfunction 
were not excluded.
According to a recent systematic review by Hackett and 
Anderson,64 some consistent identification has been positively 
associated with depression following stroke, such as stroke 
severity, physical disability, and cognitive impairment.
Diagnosis of PSD
Diagnosis of PSD in stroke survivors may be difficult due 
to the presence of other symptoms such as common cogni-
tive impairments, including aphasia, agnosia, apraxia, and 
memory problems.65 On the other hand, many methods of 
diagnosing depression rely on somatic symptoms that, in 
turn, may complicate the diagnosis of PSD.46 In case of 
the presence of depression and somatic diseases, diagnosis 
and treatment of PSD are even more complicated and have 
adverse impact on the clinical presentations and prognosis 
of the underlying disease.46 However, evaluation of depres-
sion among elderly stroke patients is more complex due to 
influence of somatic conditions, such as cognitive, sensory, 
and language impairments. Also certain challenging factors 
might overlap typical symptoms of depression from normal 
signs of aging and stroke disease, including thoughts regard-
ing death, reduced sleep, fatigue, and loss of libido.
In brief, following factors contribute to the difficulty of 
diagnosing PSD: (1) overlapping signs and symptoms of 
stroke and depression, which are indistinguishable to each 
other, to the patient and providers, (2) lack of proper train-
ing in mental health care professionals to recognize which 
symptoms are more related to stroke than depression, and 
(3) medical care providers usually have limited knowledge 
about the differences between depression and “typical” signs 
of aging and stroke.57 Therefore, clinicians should define a 
set of valid criteria for diagnosis of PSD.66 Some scientists 
believe that symptom profile of PSD is similar to that of 
nonstroke depression; therefore, diagnosis criteria should be 
the same for both,40 but it is not commonly agreed on among 
all clinicians and researchers.67
Screening and evaluation of PSD
Unfortunately, there are not many researches and data 
regarding diagnostic criteria of PSD, but 2 reports suggest 
that using the Geriatric Depression Scale (GDS) has been 
reasonable in the elderly patients.68 This 15-item short form 
questionnaire has been studied widely and is validated in a 
number of patients, and it is easy to administer.69 The GDS 
is most useful in diagnosis of depression among patients 
who are in higher functioning levels and have mild cogni-
tive impairment.70 Several authors have suggested that this 
scale instead of other scales, like the Hospital Anxiety and 
Depression Scale (HADS), to be most satisfactory screening 
instrument for PSD.68,71,72 Neurologists can easily try GDS 
on a wide range of patients.73 GDS has been used to identify 
PSD in Caucasian patients in acute inpatient and rehabilita-
tion conditions.74 Also GDS has performed relatively well 
as a screening method in Caucasian patients with stroke72 
(Table 2).
In a recent clinical trial, Healey et al screened 49 elderly 
stroke patients for depression.77 They compared 3 depression 
scales: Brief Assessment Schedule Depression Cards (BAS-
DEC), the Beck Depression Inventory-Fast Screen (BDI-FS), 
and the HADS. They showed that BASDEC and BDI-FS have 
adequate internal consistency. The BASDEC compared with 
BDI-FS had some benefits in criterion   validity in elderly stroke Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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patients. Regarding the criterion at the examined cutoffs, 
the BDI-FS and HADS were less accurate in relation. The 
BASDEC was developed to evaluate depression in elderly 
patients in a hospital ward environment.78 It is a 19-question 
measure that tests depression symptoms, each question on a 
separate card (8.2 cm × 10.4 cm), and the maximum score 
is 21. Higher scores of BASDEC indicate worse function. 
It has shown a very good sensitivity (.0.80), specificity 
(.0.90), and accuracy in predicting clinical results of medi-
cally ill elderly patients.79 Both GDS and BASDEC are not 
time-consuming to administer, and they are relatively free of 
somatic symptoms.80 Adshead et al78 showed that agreement 
between the 2 scales was high. However, McCrea et al80 
found that BASDEC was easier to administer. In a systematic 
review, Hackett and Anderson64 recommended that the gold 
standard method for diagnosis PSD is using a semistructured 
psychiatric interview, which meets all the standards needed 
for a specific diagnostic criterion (such as DSM criteria or 
International Classification of Diseases). According to the 
current diagnostic criteria of DSM-IV-TR, 5 or more symptoms 
must be present at least over a 2-week period for receiving a 
major depression diagnosis81 (Table 3). Less severe forms of 
depressive disorder, which might not meet criteria for major 
depression, have been diagnosed as either minor depression 
or dysthymic disorder. This diagnosis requires at least the 
presence of 1 major criterion symptom and a minimum of 
1 and a maximum of 4 of the specific symptoms in a 2-year 
course of chronic depressive manifestations.57
Management strategies of PSD
There is no reason to refuse any kind of treatment to elderly 
patients with PSD based on age alone, as many older indi-
viduals had a high baseline life quality and expectancy for 
many more years. A key problem, which can be mentioned 
as a factor leading to undertreatment of PSD, is that both the 
patient and the doctor often do not accept this condition as 
a treatable illness.83 A more worrying problem is that when 
evaluating an older patient, the physician concentrates on 
other aspects of the patient and dismisses the depressive 
symptoms. Unfortunately, it has been estimated that 80% 
of the PSD patients might be missed by nonpsychiatric 
clinicians.84
Meanwhile, early diagnosis of PSD is extremely impor-
tant to make an efficient treatment plan for the patient. The 
importance of an early recognition and diagnosis of PSD is 
widely agreed upon to improve functional and psychosocial 
outcomes.85 All treatments must be modified to individual 
needs based on patient’s needs, including cost, accessibil-
ity, and availability of treatments.64 Effective treatment will 
generally include the participation of the family and other 
support networks.64 In all circumstances, it is recommended 
that the treating clinician supervise a person presenting with 
depression at least weekly for the first 6 weeks to evaluate 
mood changes, suicidal thinking, physical safety, the person’s 
social life, and adverse effects of any drugs that have been 
prescribed.64
Major goals of such a treatment include reducing depres-
sive symptoms, improving mood and quality of life, using 
health care resources appropriately, and reducing the risks of 
medical complications.86 The management of PSD includes 
pharmacotherapy, psychotherapy,6 and electroconvulsive 
therapy (ECT), used especially in those with severe depres-
sive illness.
Pharmacological treatment
Despite more than 100 years of studies of PSD, there are still 
several challenges regarding PSD pharmacotherapy, includ-
ing determining its effectiveness.87 Pharmacotherapy may 
be particularly complicated in elderly PSD individuals, who 
often have high rates of medical comorbidity, concomitant 
Table 2   Characteristics  of  Geriatric  Depression  Scale   
(15-item)18,24,70,75,76
• Screening depression in elderly people
• Focus on affective rather than somatic components
• Female gender and cognitive impairment affect sensitivity
• Possible depression (cutoff $6)
• Clinically important depressive symptoms (cutoff $8)
• Self-administered test comprised yes or no questions
• Sensitivity in elderly stroke patients: 89% (cutoff 6.6)
• Specificity in elderly stroke patients: 73% (cutoff 6.6)
• Positive predictive values in elderly stroke patients: 37% (cutoff 6.6)
• Negative predictive values in elderly stroke patients: 98% (cutoff 6.6)
Table 3 Diagnostic criteria of DSM-IV  81,82
• Depressed mood most of the day
•   Markedly diminished interest or pleasure most of the day, 
nearly every day
• Significant decrease in weight or appetite
• insomnia or hypersomnia
• Psychomotor agitation or retardation, observable by others
• Fatigue or loss of energy
• Feeling of worthlessness or inappropriate guilt
• Diminished ability to concentrate or make decisions
• Recurring thoughts of death or suicidal thoughts or plans
Abbreviation: DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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polypharmacy, and more vulnerability to the adverse effects 
of antidepressants (ADs). It is important that the AD used 
should not only be effective in controlling mood disorders 
but also lack adverse effects on cognitive functions, which 
is particularly relevant to patients who have had strokes 
and more or less cognitive impairments46 (Table 4). There 
are many variables involved in pharmacotherapy of elderly 
patients, including pharmacokinetic changes associated with 
aging, drug interactions with other medications, preexisting 
illnesses, and adverse effects of the drugs on the elderly due 
to their increased vulnerability.
AD drugs
ADs can be effective in most moderate and severe depres-
sive disorders but are generally not indicated in mild forms 
because the balance of benefit and risk is not satisfactory in 
elderly stroke patients. Even when depression is properly 
diagnosed in elderly patients, they still may not receive the 
medication they require,88 and because of possible severe side 
effects of ADs in elderly patients, more often the clinicians 
avoid prescribing such medications to them.88 Unfortunately, 
even when AD treatment is administered for an old patient, 
it is mostly in inadequate doses and for shorter durations 
than recommended.89
Until now, there is no evidence for using pharmacologi-
cal or psychotherapeutic methods for PSD prevention after 
stroke,85,90,91 and a Cochrane meta-analysis of PSD treat-
ment trials confirmed that there was no sufficient indication 
to suggest drug treatment specifically for the remission of 
PSD or its prevention.85,91 In a recent systematic review of 
trials on pharmacological therapy in PSD, Hackett et al92 
reported that although ADs were able to reduce mood 
disorder symptoms, they had no clear effect on prevention 
or remission of depressive illness after stroke. However, 
a double-blind, placebo-controlled study performed by 
  Robinson et al93 showed that escitalopram as preventive 
active drug, compared with placebo over the first year after 
stroke, decreased the frequency of PSD. However, the over-
all benefit when potential side effects and complications of 
active treatment are considered is still unclear.
Table 4   Criteria  for  ideal  antidepressant  choice  in  elderly 
patients
• Unaltered drug handling in old age
• interaction free
• Safe in frail subjects with comorbid illnesses
• Simple dose regimen
• well tolerated
• Rapid onset of antidepressant action
Table 5 Antidepressants mostly used in late-life depression
Tricyclic antidepressants65,87
Nortriptyline
  The first choice among TCAs
  its use may be limited because of side effects
  The best studied drug among TCAs
  Dose: 20 mg
Side effects
    Anticholinergic effects: glaucoma, confusion, urinary retention,  
and blurring of vision
  Antiadrenergic activity: hypotension and dizziness
Selective serotonin reuptake inhibitors (SSRis)
  First-line agent in PSD treatment
    Generally considered to be the preferred first-line treatment  
for late-life depression
  No strong data recommending one SSRi over another
    Paroxetine, fluvoxamine, and escitalopram have not been studied  
for either treatment or prevention of PSD
Fluoxetine
  Most studied SSRi in PSD
  20 mg/d appears to be safe
Citalopram
  Most selective SSRi
  Less potent, highly selective, may be ranked second among SSRis
  Third most studied SSRi in PSD
  Dose: 50 mg
Sertraline
  Second most studied SSRi in both treatment and prevention of PSD
  initial dose of 50 mg/d and later up to 200 mg/d
Abbreviations: TCAs, tricyclic antidepressants; PSD, poststroke depression.
The choice of ADs
For the choice of ADs in PSD, the comparative information is 
quite limited, and none of them is specific to PSD. Selective 
serotonin reuptake inhibitors (SSRIs) are the first choice of 
PSD treatment in elderly patients due to their lower potential 
for drug interaction and side effects. Drug group, efficacy, 
and side effects of different medications are presented in 
Tables 5 and 6.
Stimulant medications
For many years, stimulant medications have been employed 
in stroke rehabilitation and in PSD, but large randomized 
clinical trials are still lacking. During 1950s, methylphenidate 
(MPH) was reported to be an effective treatment for geriatric 
depression,94 and case reports of Kaufman and his cowork-
ers80 also suggested the efficacy of MPH for PSD. Lingam 
et al conducted a retrospective study on the efficacy and side 
effects of MPH by systematically reviewing hospital charts of 
25 depressed stroke patients, who were treated with MPH.95 
The result of this study suggested a high degree of efficacy 
(80% improvement of depressive symptom) and a relatively 
low incidence of side effects. In a retrospective study, Lazarus 
et al96 reviewed hospital charts of older adults with stroke Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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and major depression. Among studied cases, 30 were treated 
with nortriptyline and 28 with MPH. Symptoms of depres-
sion resolved in 53% of MPH-treated patients and 43% of 
nortriptyline-treated patients, which showed no significant 
difference.96 However, a more significant difference was 
observed in response time. In MPH-treated patients, the mean 
response time to peak effect was 2.4 days compared with 
27 days for nortriptyline-treated patients. Also, side effects 
were reported in 14% of MPH-treated patients and 30% of 
nortriptyline-treated patients, including delirium, requiring 
termination of nortriptyline therapy in 2 patients.96 They 
also prospectively studied MPH administration for elderly 
stroke patients (mean age, 73 years),97 which was started at 
a dose of 2.5–5 mg in the morning and at noon, which was 
slowly increased to 40 mg/d. Mean dosage used at about 
the 10th day was 17 mg/d. Interestingly, over 3 weeks of 
therapy, 80% of patients showed a full or partial response 
based on Hamilton Depression Rating Scale. MPH was 
shown to be a safe and efficient therapy for elderly patients 
with PSD. Fast onset of action (usually within 3–10 days) and 
relatively few adverse effects of MPH may offer significant 
benefits over tricyclic ADs (TCAs), whose onset of action 
needs 2–4 weeks.97 It can be concluded that specifically in 
  conditions where patients’ active participation in the recovery 
process is essential and issues like limitations in insurance 
coverage and subsequently shorter hospital stays, prescribing 
MPH would be best option.
In another prospective, randomized, double-blind, 
placebo-controlled study, Grade et al98 compared MPH and 
placebo among PSD patients. MPH was started at 5 mg and 
increased gradually to 30 mg (15 mg at 8:00 am and 15 mg 
at 12:00 noon). After a 3-week treatment period with MPH 
(or placebo) in conjunction with physical therapy, the results 
confirmed that MPH is a safe and efficient adjunct therapy 
in the rehabilitation of acute stroke patients. MPH therapy 
has many benefits, including mood elevation, better motor 
functioning, and the ability to conduct regular daily activities 
without any considerable side effects.
Course of drug treatment
Based on the guidelines of the American College of Physi-
cians, antidepressive drugs should be continued at least for 
4 months after initial recovery and should be changed if no 
response has been seen after 6 weeks.99 AD treatment also 
should be continued for a minimum of 6 months in those 
patients with response to therapy. Later on, AD treatment 
can be slowly withdrawn, or in case of relapse, it can be 
continued for a longer duration.65,100 ADs should also be 
prescribed to patients with moderate to severe depression 
even before psychological interventions, and they should be 
continued for at least 4–6 weeks, at the doses recommended 
by the manufacturer64 (Figure 1).
Nonpharmacological management
Several reasons have been suggested in favor of nonpharma-
cological management, including the possibility of compli-
cations, which may occur when treating elderly depressed 
individuals due to adverse effects of the ADs, their inability 
to modify adverse environmental stressors, and a lack of 
social support factors, which often respond to a psychological 
approach.18 Nonpharmacological interventions in PSD have 
included psychotherapy, ECT, and transcranial magnetic 
stimulation. Psychological interventions are the preferred 
method of treatment for mild mood disorders64 and are 
reserved for those in whom ADs are either inappropriate or 
not tolerated.101 In most psychological treatments, a behav-
ioral activation component is often involved, which treats 
the problem of activity limitation. Although some of these 
approaches mainly focus on the meaningfulness of the activ-
ity during the treatment, the possibility of targeting depres-
sion and intensifying and maintaining cognitions has also 
been practiced.24 Psychological treatments include behavioral 
therapy, cognitive behavioral therapy (CBT), problem-solving 
therapy, and life review therapy.102 Also, Watkins et al103 have 
recently shown that motivational interviewing is effective, 
leading to improved patients’ mood 3 months after stroke. 
Unfortunately, there are some drawbacks for these interven-
tions, including their costs in terms of staff time and expertise 
and their slow and delayed response, which requires several 
weeks before showing any clinical improvements.
Table 6 Comparison of SSRis with TCAs24,86,91
• Faster onset of action compared with TCAs
• At least as effective as the TCAs
• SSRIs have a more favorable safety profile
•   SSRis are generally not affected by age-related alterations  
in drug metabolism
•   SSRis can be administered in a simple, once-daily regimen,  
less confusing for elderly patients
•   improved tolerability of the SSRis makes them a more appropriate 
choice for elderly patients
• SSRis do not cause the anticholinergic effects like TCAs
•   TCAs are potentially fatal in overdose (great concern in elderly  
PSD patients who are at increased risk of suicide)
•   SSRis are associated with a lower potential of drug interaction 
compared with TCAs
• A safer side-effect profile compared with TCAs
Abbreviations:  SSRis,  selective  serotonin  reuptake  inhibitors;  TCAs,  tricyclic 
antidepressants; PSD, poststroke depression.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Cognitive behavioral therapy
CBT has a very strong and positive effect on patients because it 
not only improves and builds confidence but also enhances the 
daily lifestyle of the patients through a range of activities. The 
treatment requires qualified health professionals to constantly 
evaluate the participants, making it easier to satisfy the diverse 
needs of the individuals. By this method, CBT is designed to 
challenge dysfunctional thoughts or beliefs that are associated 
with low mood and to collaboratively establish more functional 
thoughts or beliefs.66 However, patients with cognitive impair-
ment and/or aphasia are not suited to this treatment form.
CBT is based on giving insights towards psychoeducation, 
collaborative empiricism, active problem solving, assessing 
the nature and quality of supports, and improvement of the 
adaptation to the new lifestyle after a stroke.104 Patients will 
find out how their thoughts may contribute to affective symp-
toms and feelings and how they can transform them.105
For individuals diagnosed with a range of chronic dis-
abling physical conditions, such as stroke and PSD, a 12-week 
course of CBT, as advised and conducted by Kemp et al was 
shown effective.106
In general, approximately 6–8 regular sessions should be 
provided to patients over a period of 10–12 weeks, with most 
people experiencing an improvement in mood and/or a reduc-
tion in symptoms after 2 months of therapy. Response to ther-
apy should be reviewed after 8 sessions. A therapy extension 
period of 6 months is considered necessary for a person who 
has multiple issues or severe comorbidity.64 Psychotherapy 
should be combined with ADs to reduce residual symptoms 
and the risk of relapse in patients with severe depression107 and 
in those with moderate or severe depression who refuse to take 
ADs.107 However, in a randomized controlled trial, Lincoln 
et al108 showed that CBT in the treatment of PSD was not 
effective, and they suggested that further evaluation with large 
sample size is needed to more clearly assess the role of CBT 
in PSD. Also in a Cochrane review for depression intervention 
after stroke, it was shown that psychotherapeutic intervention 
for PSD has failed to provide evidence for effectiveness.85
electroconvulsive therapy
ECT should only be used to achieve rapid and short-term 
improvement of severe depressive symptoms after other 
treatments have proven ineffective. It is not recommended as 
a primary or maintenance therapy for PSD.109 It is used more 
often in older adults compared with any other age group. 
Its primary indication is severe depressive illness or when 
a disorder (or its symptoms) is considered potentially life 
threatening.64 A retrospective review of patients treated with 
ECT showed improvement in 95% of PSD.110 Approximately 
50% of patients had a prestroke history of major depression 
or alcoholism, and 85% already had received antidepressive 
medications to which they did not respond or were intolerant. 
Moderate to severe PSD 
Antidepressant therapy for ≥4–6 weeks  
No improvement/no reduction in symptoms
Does the patient follow the treatment plan? 
No
Treatment should continue about 9–12 months 
The treatment plan should be accurately followed 
1. Another antidepressant should be prescribed
Yes
Improvement/reduction in symptoms
2. OR, psychotherapy should be added
Figure 1 Flow chart of antidepressant therapy.
Abbreviation: PSD, poststroke depression.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Management of depression
According to the results obtained from 2 small samples of 14 
and 20 PSD patients,111,112 approximately 40% of patients had a 
relapse of depressive symptoms after ECT in the short term111 and 
20% developed medical complications.112 ECT is therefore not a 
recommended therapy for depressed stroke patients, and adverse 
events such as cardiac complications, memory loss, and delirium 
suggest caution with the use of ECT for older PSD patients.64
Key issues
•  Monitoring and assessing for depression are highly recom-
mended after stroke, particularly for those having risk factors 
associated with PSD development, and delivering proper 
management, in the case of confirmed diagnosis.
•  To improve recovery, facilitate rehabilitation, and decrease 
mortality, early recognition of PSD is required.
•  Some factors, including older age, female sex, stroke severity, and 
functional dependence, further contribute to PSD development.
•  There are a number of factors that make treatment more 
complicated in the elderly patient, including the high rate 
of comorbid disorders and often an increased sensitivity to 
possible side effects of medications.
•  Evidence does not show any association between severity of 
PSD and side effect of stroke lesion.
•  Frequency of depressive disorders in elderly patients is higher 
than the frequency of depressive disorders in age- and sex-
matched controls.
•  Despite serious mood disorders occurring after stroke, no 
reliable evidence-based clinical management method has 
existed so far.
•  Treatment might be more demanding in elderly patients 
because of factors like the high rate of comorbid disorders 
and often an increased sensitivity to the side effects of 
medication.
•  SSRIs have been found to be superior to TCAs in treatment 
of depression in old age.
•  MPH appears to be a safe and effective treatment for elderly 
stroke patients with PSD.
•  More advanced standard screening and diagnostic tools and 
more effective and safer treatments will help not only to treat 
this patient population effectively but also to decrease health 
care burden and costs.
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